Literature DB >> 32503270

HMGA Proteins in Hematological Malignancies.

Angela Minervini1, Nicoletta Coccaro1, Luisa Anelli1, Antonella Zagaria1, Giorgina Specchia1, Francesco Albano1.   

Abstract

The high mobility group AT-Hook (HMGA) proteins are a family of nonhistone chromatin remodeling proteins known as "architectural transcriptional factors". By binding the minor groove of AT-rich DNA sequences, they interact with the transcription apparatus, altering the chromatin modeling and regulating gene expression by either enhancing or suppressing the binding of the more usual transcriptional activators and repressors, although they do not themselves have any transcriptional activity. Their involvement in both benign and malignant neoplasias is well-known and supported by a large volume of studies. In this review, we focus on the role of the HMGA proteins in hematological malignancies, exploring the mechanisms through which they enhance neoplastic transformation and how this knowledge could be exploited to devise tailored therapeutic strategies.

Entities:  

Keywords:  HMGA proteins; hematologic malignancies; molecular markers; targeted therapy

Year:  2020        PMID: 32503270     DOI: 10.3390/cancers12061456

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  3 in total

1.  Circular RNA CircSHKBP1 accelerates the proliferation, invasion, angiogenesis, and stem cell-like properties via modulation of microR-766-5p/high mobility group AT-hook 2 axis in laryngeal squamous cell carcinoma.

Authors:  Fu Chen; Haiyan Zhang; Jie Wang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

2.  [Prognostic implications and functional enrichment analysis of LTB4R in patients with acute myeloid leukemia].

Authors:  X Zhang; X Zhang; P Liu; K Liu; W Li; Q Chen; W Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-03-20

3.  HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel.

Authors:  Barbara Belletti; Guidalberto Manfioletti; Michela Sgubin; Silvia Pegoraro; Ilenia Pellarin; Gloria Ros; Riccardo Sgarra; Silvano Piazza; Gustavo Baldassarre
Journal:  Cell Death Dis       Date:  2022-05-03       Impact factor: 9.685

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.